Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome-
and immune-targeted drugs that have transformed the outcomes of some malignancies 1 . …

… DE Piccioni is an employee/paid consultant for Tocagen. CK Anders is an employee/paid
consultant for Genentech, Eisai, IPSEN, Seattle Genetics, and PUMA, reports receiving …

By profiling their patients' tumors, oncologists now have the option to use molecular results
to match patients with drug(s) based on specific biomarkers. In this observational study, 347 …

… We retrospectively reviewed the liquid biopsy results of 171 consecutive de-identified …
Analysis was performed per UCSD IRB exempt approval for study of pre-existing de-identified data…

Purpose: There is a growing interest in using circulating tumor DNA (ctDNA) testing in
patients with cancer. Experimental Design: A total of 168 patients with diverse cancers were …

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor
sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic …

… We retrospectively reviewed the liquid biopsy results of 670 consecutive, de-identified …
Review Board exempt approval for study of preexisting de-identified data and the Declaration of …

PURPOSE Patients with progressive or recurrent meningiomas have limited systemic therapy
options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with …

Despite the increased use of molecular diagnostics, the extent to which patients who have
these tests harbor potentially actionable aberrations is unclear. We retrospectively reviewed …